LinkedIn Profile

Access Adaptimmune Therapeutics historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal GICS Sector GICS Industry
nasdaq:adap 9045855 Jun 4th, 2020 12:00AM Adaptimmune 14K 367.00 Open Biotechnology Jun 4th, 2020 12:26PM Jun 4th, 2020 12:26PM Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Open Open 60 Jubilee Avenue, Milton Park Abingdon Oxfordshire GB OX14 4RX Health Care Pharmaceuticals & Biotechnology
nasdaq:adap 9045855 Jun 3rd, 2020 12:00AM Adaptimmune 14K 366.00 Open Biotechnology Jun 2nd, 2020 10:04PM Jun 2nd, 2020 10:04PM Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Open Open 60 Jubilee Avenue, Milton Park Abingdon Oxfordshire GB OX14 4RX Health Care Pharmaceuticals & Biotechnology
nasdaq:adap 9045855 Jun 2nd, 2020 12:00AM Adaptimmune 14K 366.00 Open Biotechnology Jun 2nd, 2020 11:28AM Jun 2nd, 2020 11:28AM Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Open Open 60 Jubilee Avenue, Milton Park Abingdon Oxfordshire GB OX14 4RX Health Care Pharmaceuticals & Biotechnology
nasdaq:adap 9045855 Jun 1st, 2020 12:00AM Adaptimmune 14K 364.00 Open Biotechnology May 31st, 2020 10:04PM May 31st, 2020 10:04PM Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Open Open 60 Jubilee Avenue, Milton Park Abingdon Oxfordshire GB OX14 4RX Health Care Pharmaceuticals & Biotechnology
nasdaq:adap 9045855 May 31st, 2020 12:00AM Adaptimmune 14K 362.00 Open Biotechnology May 30th, 2020 10:04PM May 30th, 2020 10:04PM Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Open Open 60 Jubilee Avenue, Milton Park Abingdon Oxfordshire GB OX14 4RX Health Care Pharmaceuticals & Biotechnology
nasdaq:adap 9045855 May 30th, 2020 12:00AM Adaptimmune 14K 362.00 Open Biotechnology May 30th, 2020 12:49PM May 30th, 2020 12:49PM Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Open Open 60 Jubilee Avenue, Milton Park Abingdon Oxfordshire GB OX14 4RX Health Care Pharmaceuticals & Biotechnology
nasdaq:adap 9045855 May 29th, 2020 12:00AM Adaptimmune 14K 361.00 Open Biotechnology May 28th, 2020 10:04PM May 28th, 2020 10:04PM Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Open Open 60 Jubilee Avenue, Milton Park Abingdon Oxfordshire GB OX14 4RX Health Care Pharmaceuticals & Biotechnology
nasdaq:adap 9045855 May 28th, 2020 12:00AM Adaptimmune 14K 361.00 Open Biotechnology May 28th, 2020 10:53AM May 28th, 2020 10:53AM Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Open Open 60 Jubilee Avenue, Milton Park Abingdon Oxfordshire GB OX14 4RX Health Care Pharmaceuticals & Biotechnology
nasdaq:adap 9045855 May 27th, 2020 12:00AM Adaptimmune 14K 361.00 Open Biotechnology May 26th, 2020 10:04PM May 26th, 2020 10:04PM Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Open Open 60 Jubilee Avenue, Milton Park Abingdon Oxfordshire GB OX14 4RX Health Care Pharmaceuticals & Biotechnology
nasdaq:adap 9045855 May 26th, 2020 12:00AM Adaptimmune 14K 362.00 Open Biotechnology May 26th, 2020 08:28AM May 26th, 2020 08:28AM Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Open Open 60 Jubilee Avenue, Milton Park Abingdon Oxfordshire GB OX14 4RX Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.